Page 3 - Program Products News Today

Good morning, everyone. It is monday, march 20th. Im alex witt alongside ayman hol mohyeldin and louis burgdorf. Today they will hold the first hearing into the meddling of the president ial election. James comey and Admiral Mike Rogers are likely to face questions on the series of tweets that the president sent on saturday morning a couple weeks ago. And two days ago accusing president obama of ordering a wiretap of his phones at trump tower. Comey reportedly requested that the Justice Departme...

Hes the author of a new book, the geraldo show, the memoirs. And youre outnumbered. I think we are. Youre a veteran, youre old and lame. Your book is so juicy. I thought you brought a pack of peaches. I saw some in the back. There are some peaches here. Careful. Im old and lame. I can say things like that. Goodness. Lets move on before we get in trouble. The kremlin is claiming President Trump invited Vladimir Putin to a summit at the white house. Thats according to russias state news agency. It...

DGAP-News: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates 26.05.2021 / 13:00 CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates - - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose - CureVac participating in broad UK trial evaluating di...

DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 15.04.2021 / 13:30 CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Eu...

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of s...